Agios Pharmaceuticals (AGIO) vs Trevi Therapeutics (TRVI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Trevi Therapeutics (TRVI) has outperformed Agios Pharmaceuticals (AGIO) over the past year, gaining 37.6% versus a loss of 22.2%. Over five years, TRVI leads with a +918.6% price change compared with -31.3% for AGIO. Agios Pharmaceuticals is the larger company by market cap ($1.87 billion vs $1.77 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGIO | TRVI |
|---|---|---|
| Share price | $31.40 | $12.39 |
| Market cap | $1.87B | $1.77B |
| 1-day change | -1.22% | -5.71% |
| YTD return | +16.79% | +4.95% |
| 1-year return | -22.22% | +37.59% |
| 5-year return | -31.31% | +918.60% |
| EPS (TTM) | $-7.03 | $-0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $46.00 | $20.22 |
| 52-week low | $22.24 | $9.28 |
| Distance from 52-week high | -31.74% | -38.72% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +46.50% | +127.44% |
| Average volume | 1.05M | 1.95M |
| Shares outstanding | 59.70M | 142.48M |
| Employees | 539 | 34 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TRVI has outperformed AGIO by 59.8 percentage points over the past year.
About Agios Pharmaceuticals
AGIO stock →Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.
Health Care · Biotechnology: Pharmaceutical Preparations · 539 employees
About Trevi Therapeutics
TRVI stock →Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
AGIO vs TRVI FAQ
Which is bigger, Agios Pharmaceuticals or Trevi Therapeutics?
Agios Pharmaceuticals (AGIO) is larger, with a market capitalization of $1.87B compared with $1.77B for Trevi Therapeutics (TRVI).
Which stock has performed better over the past year, AGIO or TRVI?
TRVI returned +37.59% over the past 12 months, compared with -22.22% for AGIO (price return, excluding dividends). Past performance does not predict future results.
Are Agios Pharmaceuticals and Trevi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.